ClinicalTrials.gg
CompletedNCT05117489Updated Aug 19, 2024

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

A Phase 1 interventional study of Miricorilant 150 mg and Miricorilant 100 mg in Nonalcoholic Steatohepatitis (NASH), sponsored by Corcept Therapeutics. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
198th of 460
70 · median 56
Started
2021
with 56 others
Phase 1
79 of 547
6 open now
Registered
423rd of 547
by date
Lead sponsor
8 of 547
Corcept Therapeutics

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 198th largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 79 in phase 1, and was the 423rd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)

Read the detailed description

This phase 1b, Open-Label Study will assess the safety, efficacy and pharmacokinetics (PK) of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH).

Patients who meet the criteria for the study CORT-118335-861 will be enrolled on Day 1 into 1 of 11 cohorts and receive:

  • Cohort 1 - a daily dose of 150 mg of miricorilant over 24 weeks.
  • Cohort 2 - a daily dose of 150 mg of miricorilant over 12 weeks.
  • Cohort 3 - a daily dose of 100 mg of miricorilant over 2 weeks, followed by 10 weeks of dosing at 100 mg miricorilant every Monday, Wednesday and Friday.
  • Cohort 4 - a daily dose of 100 mg of miricorilant over 2 weeks, followed by 10 weeks of dosing at 100 mg miricorilant every Monday and Friday.
  • Cohort 5 - a thrice weekly dose of 100 mg of miricorilant over 12 weeks every Monday, Wednesday, and Friday.
  • Cohort 6 - a twice weekly dose of 100 mg of miricorilant over 12 weeks every Monday and Friday.
  • Cohort 7 - a daily dose of 50 mg of miricorilant over 12 weeks.
  • Cohort 8 - a daily dose of 100 mg of miricorilant over 12 weeks.
  • Cohort 9 - a daily dose of 30 mg of miricorilant over 12 weeks.
  • Cohort 10 - a once weekly dose of 200 mg of miricorilant over 12 weeks.
  • Cohort 11 - a twice weekly dose of 150 mg miricorilant over 12 weeks.
03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)

Keywords

  • Nonalcoholic Steatohepatitis
  • NASH
  • Nonalcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Have a diagnosis of NASH based on a obtained within the last year OR Have a diagnosis of presumed NASH based on blood tests and scans

Exclusion criteria

Exclusion Criteria:

  • Have participated in another clinical trial within the last year and received active treatment for NASH
  • Have participated in another clinical trial for any other indication within the last 3 months
  • Are pregnant or lactating women
  • Have a \<18 kg/m2
  • Have had liver transplantation or plan to have liver transplantation during the study
  • Have type 1 diabetes or poorly controlled type 2 diabetes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Cohort 1 - 150 mg of miricorilant for 24 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 24 weeks.

    Drug: Miricorilant 150 mg

  • Experimental
    Cohort 2 - 150 mg of miricorilant for 12 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 12 weeks.

    Drug: Miricorilant 150 mg

  • Experimental
    Cohort 3 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MWF for 10 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily for 2 weeks, followed by 100 mg of miricorilant every Monday, Wednesday and Friday for 10 weeks.

    Drug: Miricorilant 100 mg

  • Experimental
    Cohort 4 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MF for 10 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 2 weeks, followed by 100 mg of miricorilant every Monday and Friday for 10 weeks.

    Drug: Miricorilant 100 mg

  • Experimental
    Cohort 5 - 100 mg of miricorilant every MWF for 12 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday, Wednesday and Friday for 12 weeks.

    Drug: Miricorilant 100 mg

  • Experimental
    Cohort 6 - 100 mg of miricorilant every MF for 12 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday and Friday for 12 weeks.

    Drug: Miricorilant 100 mg

  • Experimental
    Cohort 7 - 50 mg of miricorilant daily for 12 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 50 mg once daily, for 12 weeks.

    Drug: Miricorilant 50 mg

  • Experimental
    Cohort 8 - 100 mg of miricorilant daily for 12 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 12 weeks.

    Drug: Miricorilant 50 mg

  • Experimental
    Cohort 9 - 30 mg of miricorilant daily for 12 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 30 mg once daily, for 12 weeks.

    Drug: Miricorilant 10 mg

  • Experimental
    Cohort 10 - 200 mg of miricorilant once a week for 12 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 200 mg once weekly, for 12 weeks.

    Drug: Miricorilant 50 mg

  • Experimental
    Cohort 11 - 150 mg of miricorilant twice weekly for 12 weeks

    Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg twice weekly for 12 weeks.

    Drug: Miricorilant 50 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Relative change from Baseline in liver-fat content assessed by MRI-PDFF compared to Baseline.

    Time frame: Baseline Day 1 up to Week 24

Secondary outcomes

  1. Change from Baseline in aspartate aminotransferase (AST).

    Time frame: Baseline Day 1 up to Week 24

  2. Change from Baseline in alanine aminotransferase (ALT).

    Time frame: Baseline Day 1 up to Week 24

  3. Change from Baseline in gamma-glutamyl transferase (GGT).

    Time frame: Baseline Day 1 up to Week 24

  4. Change from baseline in enhanced liver fibrosis score (ELF).

    ELF numerical values are calculated from serum measurements of hyaluronic acid (HA), tissue inhibitor of metalloproteinases-1 (TIMP-1), and type III procollagen (PIIINP) using the formula: ELF score = 2.494 + 0.846 In \[HA\] + 0.735 In \[PIIINP\] + 0.391 In \[TIMP-1\], and range on a continuous scale. Liver fibrosis is unlikely with scores \<6.7 and increasingly likely with higher scores.

    Time frame: Baseline Day 1 up to Week 24

07

Study locations

9 sites
  • Site 207
    Chandler, Arizona 85224, United States
  • Site 209
    Tucson, Arizona 85712, United States
  • Site 214
    Panorama City, California 91402, United States
  • Site 233
    Santa Ana, California 92704, United States
  • Site 211
    Austin, Texas 78757, United States
  • Site 213
    Edinburg, Texas 78539, United States
  • Site 305
    Houston, Texas 77079, United States
  • Site 212
    San Antonio, Texas 78229, United States
  • 226
    Seattle, Washington 98105, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jan 2024, 26 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 26 months is above that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2021
First posted
Nov 11, 2021
StartActual
Nov 23, 2021
Primary completionActual
Jan 29, 2024
CompletionActual
Jan 29, 2024
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05117489
Responsible party
Sponsor
First posted
Nov 11, 2021
Start date
Nov 23, 2021
Primary completion
Jan 29, 2024
Completion
Jan 29, 2024
Last update
Aug 19, 2024

Study contacts

Kavita Juneja, MD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion